Comparison of Perceptions of Skin Condition, Product Use and Allergen Reactivity Between People with Psoriasis and Controls in the European Dermato-Epidemiology Network (EDEN) Fragrance Study
DOI:
https://doi.org/10.2340/actadv.v104.23513Keywords:
psoriasis, skin dryness, skin sensitivity, allergen reactivity, patch test, neuro-immune inflammationAbstract
Psoriasis, a chronic inflammatory skin disease, goes beyond visible symptoms and affects the general well-being of patients. The aim of this study is to understand how patients with psoriasis perceive their skin characteristics and reactivity to allergens. The study population includes 11,283 participants within the European Dermato-Epidemiology Network (EDEN) Fragrance study, covering several European regions. The study compared perceptions of skin dryness, sensitivity, product avoidance and reactivity to allergens between patients with psoriasis and controls, evaluating the potential influence of psoriasis severity. The results showed that subjects with psoriasis reported dry skin (71.1%) and sensitive skin (49.4%) more often than did controls (51.6% and 38.5%, respectively). Psoriasis patients were more likely to avoid specific products. Interestingly, there were no significant differences in patch-test results between the 2 groups and the severity of psoriasis did not have a consistent impact on these perceptions. In conclusion, people with psoriasis tend to perceive their skin as drier and more sensitive. Notably, the severity of psoriasis did not consistently influence these perceptions and objective reactivity to allergens did not align with subjective perception. Understanding these aspects is crucial for tailoring treatments to improve the well-being of patients with psoriasis, which warrants further research to explore subjective perceptions of skin well-being in patients with psoriasis.
Downloads
References
Griffiths CEM, Armstrong AW, Gudjonsson JE, Barker JNWN. Psoriasis. Lancet 2021; 397: 1301-1315.
https://doi.org/10.1016/S0140-6736(20)32549-6 DOI: https://doi.org/10.1016/S0140-6736(20)32549-6
Griffiths CE, Iaccarino L, Naldi L, Olivieri I, Pipitone N, Salvarani C, et al. Psoriasis and psoriatic arthritis: immunological aspects and therapeutic guidelines. Clin Exp Rheumatol 2006; 24: S72-S78.
Coates LC, Soriano ER, Corp N, Bertheussen H, Callis Duffin K, Campanholo CB, et al GRAPPA. Treatment Recommendations domain subcommittees Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis. Nat Rev Rheumatol 2021; 18: 465-479.
https://doi.org/10.1038/s41584-022-00798-0 DOI: https://doi.org/10.1038/s41584-022-00798-0
Korman NJ. Management of psoriasis as a systemic disease: what is the evidence? Br J Dermatol 2020; 182: 840-848.
https://doi.org/10.1111/bjd.18245 DOI: https://doi.org/10.1111/bjd.18245
Takeshita J, Grewal S, Langan SM, Mehta NN, Ogdie A, Van Voorhees AS., et al. Psoriasis and comorbid diseases: epidemiology. J Am Acad Dermatol 2017; 76: 377-390.
https://doi.org/10.1016/j.jaad.2016.07.064 DOI: https://doi.org/10.1016/j.jaad.2016.07.064
Amin, M, Lee, EB, Tsai, TF, Wu, JJ. Psoriasis and co-morbidity. Acta Derm Venereol 2020; 100: adv00033.
https://doi.org/10.2340/00015555-3387 DOI: https://doi.org/10.2340/00015555-3387
Naldi L, Mercuri SR. Epidemiology of comorbidities in psoriasis. Dermatol Ther 2010; 23: 114-118.
https://doi.org/10.1111/j.1529-8019.2010.01304.x DOI: https://doi.org/10.1111/j.1529-8019.2010.01304.x
Kleyn CE, Talbot PS, Mehta NN, Sampogna F, Bundy C, Ashcroft DM, et al. Psoriasis and mental health workshop report: exploring the links between psychosocial factors, psoriasis, neuroinflammation and cardiovascular disease risk. Acta Derm Venereol 2020; 100: adv00020.
https://doi.org/10.2340/00015555-3375 DOI: https://doi.org/10.2340/00015555-3375
Mattei PL, Corey KC, Kimball AB. Psoriasis Area Severity Index (PASI) and the Dermatology Life Quality Index (DLQI): the correlation between disease severity and psychological burden in patients treated with biological therapies. J Eur Acad Dermatol Venereol 2014; 28: 333-337.
https://doi.org/10.1111/jdv.12106 DOI: https://doi.org/10.1111/jdv.12106
Boswell ND, Cook MK, Balogh EA, Feldman SR. The impact of complete clearance and almost complete clearance of psoriasis on quality of life: a literature review. Arch Dermatol Res 2023; 315: 699-706.
https://doi.org/10.1007/s00403-022-02420-5 DOI: https://doi.org/10.1007/s00403-022-02420-5
Puig L, Thom H, Mollon P, Tian H, Ramakrishna GS. Clear or almost clear skin improves the quality of life in patients with moderate-to-severe psoriasis: a systematic review and meta-analysis. J Eur Acad Dermatol Venereol 2017; 31: 213-220.
https://doi.org/10.1111/jdv.14007 DOI: https://doi.org/10.1111/jdv.14007
Van Voorhees AS, Fried R. Depression and quality of life in psoriasis. Postgrad Med 2009; 121: 154-161.
https://doi.org/10.3810/pgm.2009.07.2040 DOI: https://doi.org/10.3810/pgm.2009.07.2040
Pithadia DJ, Reynolds KA, Lee EB, Wu JJ. Psoriasis-associated cutaneous pain: etiology, assessment, impact, and management. J Dermatolog Treat 2019; 30: 435-440.
https://doi.org/10.1080/09546634.2018.1528330 DOI: https://doi.org/10.1080/09546634.2018.1528330
Ayasse MT, Buddenkotte J, Alam M, Steinhoff M. Role of neuroimmune circuits and pruritus in psoriasis. Exp Dermatol 2020; 29: 414-426.
https://doi.org/10.1111/exd.14071 DOI: https://doi.org/10.1111/exd.14071
Ljosaa TM, Bondevik H, Halvorsen JA, Carr E, Wahl AK. The complex experience of psoriasis related skin pain: a qualitative study. Scand J Pain 2020; 20: 491-498.
https://doi.org/10.1515/sjpain-2019-0158 DOI: https://doi.org/10.1515/sjpain-2019-0158
Langan SM, Bouwes Bavinck JN, Coenraads PJ, Diepgen T, Elsner P, Grob JJ, et al, & European Dermato-Epidemiology Network. Update on the activities of the European Dermato-Epidemiology Network (EDEN). Dermatology 2006; 213: 1-2.
https://doi.org/10.1159/000092828 DOI: https://doi.org/10.1159/000092828
Naldi L, Cazzaniga S, Gonçalo M, Diepgen T, Bruze M, Elsner P, et al, & EDEN Fragrance Study Group. Prevalence of self-reported skin complaints and avoidance of common daily life consumer products in selected European Regions. JAMA Dermatol 2014; 150: 154-163.
https://doi.org/10.1001/jamadermatol.2013.7932 DOI: https://doi.org/10.1001/jamadermatol.2013.7932
Brown LD, Cai TT, DasGupta A. Interval estimation for a binomial proportion. Stat Sci 2001; 16: 101-133.12.
https://doi.org/10.1214/ss/1009213286 DOI: https://doi.org/10.1214/ss/1009213286
European Commission. Europe in figures - Eurostat yearbook 2010. Luxembourg, Publications Office of the European Union; 2010.
Ahmad OB, Boschi-Pinto C, Lopez AD, Murray CJL, Lozano R, Inoue M. Age standardization of rates: a new WHO standard. Geneva: World Health Organization; 2001.
Nordbø ECA, Aamodt G, Ihlebæk CM. Subjective health complaints in individuals with psoriasis and psoriatic arthritis: associations with the severity of the skin condition and illness perceptions - a cross-sectional study. Int J Behav Med 2017; 24: 438-446.
https://doi.org/10.1007/s12529-017-9637-4 DOI: https://doi.org/10.1007/s12529-017-9637-4
Zschocke I, Mrowietz U, Karakasili E, Reich K. Non-adherence and measures to improve adherence in the topical treatment of psoriasis. J Eur Acad Dermatol Venereol 2014; 28: 4-9.
https://doi.org/10.1111/jdv.12445 DOI: https://doi.org/10.1111/jdv.12445
Choi JW, Kim BR, Youn SW. Adherence to topical therapies for the treatment of psoriasis: surveys of physicians and patients. Ann Dermatol 2017; 29: 559-564.
https://doi.org/10.5021/ad.2017.29.5.559 DOI: https://doi.org/10.5021/ad.2017.29.5.559
Devaux S, Castela A, Archier E, Gallini A, Joly P, Misery L, et al. Adherence to topical treatment in psoriasis: a systematic literature review. J Eur Acad Dermatol Venereol 2012; 26: 61-67.
https://doi.org/10.1111/j.1468-3083.2012.04525.x DOI: https://doi.org/10.1111/j.1468-3083.2012.04525.x
Chat VS, Kearns DG, Uppal SK, Han G, Wu JJ. Management of psoriasis with topicals: applying the 2020 AAD-NPF guidelines of care to clinical practice. Cutis 2022; 110: 8-14.
https://doi.org/10.12788/cutis.0573 DOI: https://doi.org/10.12788/cutis.0573
Ninosu N, Hoelker S, Kappenstein M, Buettner S, Peitsch WK, Schaarschmidt ML. Treatment satisfaction of patients with psoriasis with topical therapy in a real-world setting: unmet need for higher effectiveness. J Dermatol Treat 2023; 34: 2200570.
https://doi.org/10.1080/09546634.2023.2200570 DOI: https://doi.org/10.1080/09546634.2023.2200570
Malhotra V, Kaur I, Saraswat A, Kumar B. Frequency of patch-test positivity in patients with psoriasis: a prospective controlled study. Acta Derm Venereol 2002; 82: 432-435.
https://doi.org/10.1080/000155502762064566 DOI: https://doi.org/10.1080/000155502762064566
Misery L, Loser K, Ständer S. Sensitive skin. J Eur Acad Dermatol Venereol 2016; 30: 2-8.
https://doi.org/10.1111/jdv.13532 DOI: https://doi.org/10.1111/jdv.13532
Singh R, Koppu S, Perche PO, Feldman SR. The cytokine mediated molecular pathophysiology of psoriasis and its clinical implications. Int J Mol Sci 2021; 22: 12793.
https://doi.org/10.3390/ijms222312793 DOI: https://doi.org/10.3390/ijms222312793
Holman DM, Kalaaji AN. Cytokines in dermatology. J Drugs Dermatol 2006; 5: 520-524.
de Alcantara CC, Reiche EMV, Simão ANC. Cytokines in psoriasis. Adv Clin Chem 2021; 100: 171-204.
https://doi.org/10.1016/bs.acc.2020.04.004 DOI: https://doi.org/10.1016/bs.acc.2020.04.004
Iznardo H, Puig L. The interleukin-1 family cytokines in psoriasis: pathogenetic role and therapeutic perspectives. Expert Rev Clin Immunol 2021; 17: 187-199.
https://doi.org/10.1080/1744666X.2021.1886081 DOI: https://doi.org/10.1080/1744666X.2021.1886081
Peters EM, Liezmann C, Klapp BF, Kruse J. The neuroimmune connection interferes with tissue regeneration and chronic inflammatory disease in the skin. Ann N Y Acad Sci 2012; 1262: 118-126.
https://doi.org/10.1111/j.1749-6632.2012.06647.x DOI: https://doi.org/10.1111/j.1749-6632.2012.06647.x
Ruppenstein A, Limberg MM, Loser K, Kremer AE, Homey B, Raap U. Involvement of neuro-immune interactions in pruritus with special focus on receptor expressions. Front Med (Lausanne) 2021; 8: 627985.
https://doi.org/10.3389/fmed.2021.627985 DOI: https://doi.org/10.3389/fmed.2021.627985
Shang L, Zhao S, Shi H, Xing X, Zhang J, He Y. Nerve growth factor mediates activation of transient receptor potential vanilloid 1 in neurogenic pruritus of psoriasis. Int Immunopharmacol 2023; 118: 110063.
https://doi.org/10.1016/j.intimp.2023.110063 DOI: https://doi.org/10.1016/j.intimp.2023.110063
Moon HS, Mizara A, McBride SR. Psoriasis and psycho-dermatology. Dermatol Ther (Heidelb) 2013; 3: 117-130.
https://doi.org/10.1007/s13555-013-0031-0 DOI: https://doi.org/10.1007/s13555-013-0031-0
Martins AM, Ascenso A, Ribeiro HM, Marto J. The brain-skin connection and the pathogenesis of psoriasis: a review with a focus on the serotonergic system. Cells 2020; 9: 796.
https://doi.org/10.3390/cells9040796 DOI: https://doi.org/10.3390/cells9040796
Galimova E, Rätsep R, Traks T, Chernov A, Gaysina D, Kingo K, et al. Polymorphisms in corticotrophin-releasing hormone-proopiomalanocortin (CRH-POMC) system genes: Neuroimmune contributions to psoriasis disease. J Eur Acad Dermatol Venereol 2023; 37: 2028-2040.
https://doi.org/10.1111/jdv.19257 DOI: https://doi.org/10.1111/jdv.19257
Amalia SN, Baral H, Fujiwara C, Uchiyama A, Inoue Y, Yamazaki S, et al. TRPV4 regulates the development of psoriasis by controlling adenosine triphosphate expression in keratinocytes and the neuroimmune system. J Invest Dermatol 2023; 143: 2356-2365.e5.
https://doi.org/10.1016/j.jid.2023.05.009 DOI: https://doi.org/10.1016/j.jid.2023.05.009
Zamirska A, Reich A, Berny-Moreno J, Salomon J, Szepietowski JC. Vulvar pruritus and burning sensation in women with psoriasis. Acta Derm Venereol 2008; 88: 132-135.
https://doi.org/10.2340/00015555-0372 DOI: https://doi.org/10.2340/00015555-0372
Additional Files
Published
How to Cite
License
Copyright (c) 2024 Fortunato Cassalia, Simone Cazzaniga, Robert Ofenloch, Peter Elsner, Margarida Gonçalo, Marie-Louise Schuttelaar , Åke Svensson, Elena Pezzolo, Magnus Bruze, Luigi Naldi
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All digitalized ActaDV contents is available freely online. The Society for Publication of Acta Dermato-Venereologica owns the copyright for all material published until volume 88 (2008) and as from volume 89 (2009) the journal has been published fully Open Access, meaning the authors retain copyright to their work.
Unless otherwise specified, all Open Access articles are published under CC-BY-NC licences, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.
